

Supplementary Table 5. Change in Laboratory Values During Double-blind Treatment Period (Safety Population)

n (%)	Adalimumab 40 mg q2w (n=184)	Sarilumab 200 mg q2w (n=184)
ALT*		
>1 to 1.5 × ULN	22 (12.0)	36 (19.6)
>1.5 to 3 × ULN	17 (9.3)	26 (14.1)
>3 to 5 × ULN	3 (1.6)	5 (2.7)
>5 to 10 × ULN	1 (0.5)	1 (0.5)
>10 to 20 × ULN	1 (0.5)	0
>20 × ULN	0	0
ALT and TBILI*		
ALT >3 × ULN and TBILI >2 × ULN	0	0
Absolute neutrophil count*		
Grade 1: ≥1.5 Giga/L to LLN	21 (11.5)	44 (23.9)
Grade 2: ≥1 to 1.5 Giga/L	5 (2.7)	31 (16.8)
Grade 3: ≥0.5 to 1 Giga/L	2 (1.1)	16 (8.7)
Grade 4: <0.5 Giga/L	0	3 (1.6)
Platelet count <100 Giga/L*		
<100 Giga/L	0	1 (0.5)
≥75 to 100 Giga/L	0	0
≥50 to 75 Giga/L	0	0
≥25 to 50 Giga/L	0	0
<25 Giga/L	0	1 (0.5)

*N=183 for adalimumab, as 1 patient did not have the parameter assessed postbaseline.

ALT, alanine aminotransferase; LLN, lower limit of normal; q2w, every 2 weeks; TBILI, total bilirubin; ULN, upper limit of normal.